A Phase Ib/IIb, Randomised, Double Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability and Clinical Activity of Humanised Antibody GSK1070806 in the Treatment of Patients With Moderate-to-Severe Crohn's Disease
Phase of Trial: Phase I/II
Latest Information Update: 02 Jan 2020
Price : $35 *
At a glance
- Drugs GSK 1070806 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms CDAID GSK1070806
- 01 Apr 2019 Status changed from not yet recruiting to recruiting.
- 10 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Dec 2018.
- 27 Sep 2018 New trial record